Sphingomyelin 16:0 is a therapeutic target for neuronal death in acid sphingomyelinase deficiency
Abstract Acid sphingomyelinase deficiency (ASMD) is a lysosomal storage disorder caused by mutations in the SMPD1 gene encoding for the acid sphingomyelinase (ASM). While intravenous infusion of recombinant ASM is an effective treatment for the peripheral disease, the neurological complications of A...
Main Authors: | Ángel Gaudioso, Xuntian Jiang, Josefina Casas, Edward H. Schuchman, María Dolores Ledesma |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2023-04-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-023-05784-2 |
Similar Items
-
Modulation of Dietary Choline Uptake in a Mouse Model of Acid Sphingomyelinase Deficiency
by: Ángel Gaudioso, et al.
Published: (2023-06-01) -
Inhibition of fatty acid amide hydrolase prevents pathology in neurovisceral acid sphingomyelinase deficiency by rescuing defective endocannabinoid signaling
by: Adrián Bartoll, et al.
Published: (2020-11-01) -
CHARACTERIZATION AND RESCUE OF THE ALTERATIONS IN OLIGODENDROCYTES MODELING THE ACID SPHINGOMYELINASE DEFICIENCY
by: Elena Melgarejo De La Peña, et al.
Published: (2023-10-01) -
Identification of a Novel Acid Sphingomyelinase Activity Associated with Recombinant Human Acid Ceramidase
by: Xingxuan He, et al.
Published: (2023-11-01) -
P349: Plasma lyso-sphingomyelin, biomarker for acid sphingomyelinase deficiency: Correlations with baseline disease and response to olipudase alfa treatment in clinical trials
by: Melissa Wasserstein, et al.
Published: (2023-01-01)